Skip to main content
. 2022 Mar 11;6(6):1651–1660. doi: 10.1182/bloodadvances.2021006415

Figure 3.

Figure 3.

Survival outcomes according to baseline ctDNA levels. (A) Progression-free survival in patients stratified by ctDNA MMPM at baseline (above and below median), (B) patients with baseline ctDNA MMPM above and below the lower quartile of quantitative values, and (C) patients with baseline ctDNA MMPM above and below the upper quartile of quantitative values. (D) OS in patients stratified by ctDNA MMPM at baseline (above and below median). INV, investigator-assessed.